Crossmark Global Holdings Inc. acquired a new position in Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 11,367 shares of the company’s stock, valued at approximately $257,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Assetmark Inc. bought a new stake in Bicycle Therapeutics in the 3rd quarter worth $34,000. GAMMA Investing LLC increased its holdings in Bicycle Therapeutics by 105.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock valued at $46,000 after purchasing an additional 1,038 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Bicycle Therapeutics by 69.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after purchasing an additional 2,918 shares during the last quarter. XTX Topco Ltd purchased a new stake in Bicycle Therapeutics in the 2nd quarter worth approximately $206,000. Finally, Natixis Advisors LLC bought a new stake in shares of Bicycle Therapeutics in the 2nd quarter worth approximately $261,000. Institutional investors own 86.15% of the company’s stock.
Bicycle Therapeutics Price Performance
BCYC opened at $20.46 on Tuesday. The firm has a market cap of $972.95 million, a PE ratio of -6.22 and a beta of 0.89. The stock has a 50-day moving average price of $24.62 and a 200-day moving average price of $23.15. Bicycle Therapeutics plc has a 1 year low of $13.07 and a 1 year high of $28.67.
Wall Street Analyst Weigh In
BCYC has been the subject of a number of research analyst reports. Stephens assumed coverage on Bicycle Therapeutics in a research note on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target for the company. Oppenheimer reaffirmed an “outperform” rating and set a $48.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, August 7th. Needham & Company LLC reissued a “buy” rating and issued a $38.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, October 31st. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.13.
Check Out Our Latest Analysis on BCYC
Insiders Place Their Bets
In related news, CEO Kevin Lee sold 3,212 shares of Bicycle Therapeutics stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $22.26, for a total value of $71,499.12. Following the completion of the sale, the chief executive officer now owns 380,864 shares of the company’s stock, valued at $8,478,032.64. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Travis Alvin Thompson sold 6,256 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $25.11, for a total value of $157,088.16. Following the completion of the transaction, the chief accounting officer now directly owns 19,241 shares in the company, valued at approximately $483,141.51. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,840 shares of company stock valued at $259,128. Corporate insiders own 8.50% of the company’s stock.
About Bicycle Therapeutics
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Recommended Stories
- Five stocks we like better than Bicycle Therapeutics
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- Canadian Penny Stocks: Can They Make You Rich?
- Applied Materials Market Capitulates: Now is the Time to Buy
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Ultra-High Dividend Yield Stocks for the New Year
Want to see what other hedge funds are holding BCYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bicycle Therapeutics plc (NASDAQ:BCYC – Free Report).
Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.